<DOC>
	<DOCNO>NCT00484432</DOCNO>
	<brief_summary>The main objective trial document response rate patient affect metastatic ovarian cancer , treat NGR-hTNF plus doxorubicin . Safety establish clinical laboratory assessment accord NCI-CTC criterion .</brief_summary>
	<brief_title>Study NGR-hTNF Combination With Doxorubicin Patients Affected Advanced Metastatic Ovarian Cancer</brief_title>
	<detailed_description>This phase II , open-label , single arm , non-randomized study conduct patient affected metastatic ovarian cancer , conduct use Simon 's two-stage design method .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Patients ≥18 year old affect advanced metastatic ovarian cancer previously treat platinum regimen ( cis carboplatin ) plus paclitaxel document progression disease within 6 month last chemotherapy administer ( refractory/resistant population ) progression disease 6 month last chemotherapy ( platinum regimens plus paclitaxel ) administer Rechallenge platinum regimens No previous exposure anthracyclines Histologically cytologically confirm ovarian carcinoma Life expectancy 3 month ECOG Performance status 0 1 Normal cardiac function ( LVEF ≥55 % ) absence uncontrolled hypertension Measurable disease define ≥1 unidimensional measurable lesion ≥ 20 mm conventional technics ≥ 10 mm ( spiral CT scan PET ) ; ascites allow present peritoneal carcinosis Adequate baseline bone marrow , hepatic renal function , define follow : Neutrophils &gt; 1.5 x 10^9/L platelet &gt; 100 x 10^9/L Bilirubin &lt; 1.5 x ULN AST and/or ALT &lt; 2.5 x ULN absence liver metastasis AST and/or ALT &lt; 5 x ULN presence liver metastasis Serum creatinine &lt; 1.5 x ULN Patients may prior therapy provide follow condition meet : Chemotherapy radiotherapy : washout period 28 day Surgery : washout period 14 day Absence condition hypervolaemia consequence ( e.g . increase stroke volume , elevate blood pressure ) haemodilution could represent risk patient ( take reference `` Technical data sheet human albumin '' specifically use Pharmacy Department NGRhTNF dilution ) Patients must give write informed consent participate study Exclusion criterion : Concurrent anticancer therapy Patients must receive investigational agent study New York Heart Association class IIIV cardiac disease Acute angina Patients myocardial infarction within last six ( 6 ) month Patient significant peripheral vascular disease Thrombosis main portal vein Clinical sign CNS involvement Patients active uncontrolled systemic disease/infections serious illness medical condition , incompatible protocol Known hypersensitivity/allergic reaction human albumin preparation excipients Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol Pregnancy lactation . Patients reproductive potential ( i.e . menopausal le 1year surgically sterilize ) must practice effective contraceptive measure throughout study . Women childbearing potential must provide negative pregnancy test ( serum urine ) within 14 day prior registration .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>NGR-hTNF</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Doxorubicin</keyword>
</DOC>